Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUM-201 in Children With Idiopathic Growth Hormone Deficiency Previously Treated With rhGH
NCT05250063Phase 2Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Feb 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ibutamoren in idiopathic growth hormone deficiency (I-GHD), sponsored by Lumos Pharma, Inc.. Started Feb 2022; status: completed.
02
Drugs
ibutamoren
03
Conditions
idiopathic growth hormone deficiency (I-GHD)
Beyond the preview
Go deeper on NCT05250063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05250063.